Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
On April 10, Jefferies reaffirmed a Buy rating and $12 price target on Iovance Biotherapeutics stock, indicating significant upside potential. Iovance Biotherapeutics Inc (IOVA): Jefferies Draws Attention Amtagvi Drug Source:unsplash Jefferies cited the strength and potential of Iovance's Amtagvi drug as factors for its renewed bullish stance on the stock. First, the firm pointed out that potential risk of competition for Amtagvi was already baked in Street's estimates for Iovance. With that, Jefferies says that the focus is more on Amtagvi commercial execution rather than competition. According to the firm, the upside for Iovance stock is based on continued Amtagvi sales growth and margin expansion. Jefferies also pointed out Amtagvi's first-mover advantage. Amtagvi is approved by the FDA as a treatment for adult patients with a type of skin cancer. It's also being investigated as a treatment for patients with lung cancer. According to Jefferies' forecast, Iovance may be ab
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026GlobeNewswire
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains? [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) had its "buy" rating reaffirmed by Chardan Capital. They now have a $16.00 price target on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 4/17/26 - Form PRE
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- IOVA's page on the SEC website